Asia in counterfeits chase; disposables penetrate high-potency API-making;

> Korea has seen a 23-fold rise in counterfeit impotence drugs over the past five years, with the majority coming from China. Article

> China's State Food and Drug Administration has provided the names of 33 fake drugs to help provincial and national authorities investigate counterfeiting. Article

> In five to ten years, disposable components may account for more than 90 percent of equipment used to make highly potent APIs. Article

> Shire will remove low-blood pressure drug ProAmatine from the market, rather than conduct the additional clinical trials the FDA has requested. Article

> Cannabis Science has licensed Denver-based RockBrook to manufacture and sell its medical marijuana formulations and delivery systems. Release

Special Report: The top counterfeit drugs. Read >>

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.